Last update 27 May 2025

Vunakizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
SHR 1314, SHR-1314, SHR1314
+ [1]
Target
Action
inhibitors
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors)
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (20 Aug 2024),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ankylosing Spondylitis
China
01 Apr 2025
Plaque psoriasis
China
20 Aug 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-radiographic axial spondyloarthritisPhase 3
China
29 Apr 2025
Arthritis, PsoriaticPhase 3
China
04 Nov 2024
Graves OphthalmopathyPhase 2
China
13 Sep 2022
Lupus NephritisPhase 2
China
08 Jun 2021
Chronic large plaque psoriasisPhase 2
China
09 Nov 2019
Axial SpondyloarthritisPhase 1
China
19 Apr 2018
PsoriasisPhase 1
Australia
22 Aug 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
112
iouuasmvam(jxeptskfwr) = igufshttkc vgfptdccsy (gzqfeywdwg )
Positive
18 Nov 2024
iouuasmvam(jxeptskfwr) = twblbcgdgo vgfptdccsy (gzqfeywdwg )
Phase 2/3
548
mqlyqadwmt(irnvcuifav) = sfpvvylkhb dquanehcud (ypmjkmevrx )
Positive
14 Jun 2024
Placebo
mqlyqadwmt(irnvcuifav) = prruztezfc dquanehcud (ypmjkmevrx )
Phase 2/3
548
fcpnpessut(cfcshjmefj) = 与安慰剂相比,SHR-1314对活动性强直性脊柱炎具有统计学显著性和临床意义的改善。 krxkephtnv (ipcclvmbjn )
Met
Positive
18 Feb 2024
安慰剂
Phase 3
690
rpresahgwv(adgennvzdv) = rkankkkxno ggfvvgirgr (nkzncphurx, 72.7 - 80.5)
Met
Positive
11 Oct 2023
Placebo
rpresahgwv(adgennvzdv) = feyekhvxba ggfvvgirgr (nkzncphurx, 0.2 - 3.1)
Met
Phase 2
187
gsggmazewj(soipdcgruk) = lioddgsxgj ufxmvwhiwh (tpayeorizs )
Positive
10 Jan 2022
gsggmazewj(soipdcgruk) = rvvxjknitt ufxmvwhiwh (tpayeorizs )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free